# A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

> **NCT06220604** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 731 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** JNJ-77242113
- **DRUG:** JNJ-77242113 Matching Placebo
- **DRUG:** Deucravacitinib
- **DRUG:** Deucravacitinib Matching Placebo

## Key facts

- **NCT ID:** NCT06220604
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-09
- **Primary completion:** 2024-11-15
- **Final completion:** 2027-09-20
- **Target enrollment:** 731 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06220604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06220604, "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06220604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*